Literature DB >> 16091223

HIV accessory proteins and surviving the host cell.

Jenny L Anderson1, Thomas J Hope.   

Abstract

Human immunodeficiency virus generates the accessory proteins Nef, viral infectivity factor (Vif), viral protein R, and viral protein U or viral protein X during viral replication in host cells. Although the significance of these accessory proteins is often lost in vitro, they are essential for viral pathogenesis in vivo. Therefore, these proteins have much potential as antiviral targets. Recent data reveal Vif perturbs an ill-defined antiviral pathway in host cells allowing HIV replication. These data highlight a common feature among HIV accessory proteins in manipulating the host to aid viral pathogenesis. Therefore, these new insights into Vif and other HIV accessory proteins are reviewed, emphasizing host cell interactions and new targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091223     DOI: 10.1007/s11904-004-0007-x

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  61 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

Review 2.  HIV accessory proteins: multifunctional components of a complex system.

Authors:  S Bour; K Strebel
Journal:  Adv Pharmacol       Date:  2000

3.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

4.  HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway.

Authors:  Anastassia D Blagoveshchenskaya; Laurel Thomas; Sylvain F Feliciangeli; Chien Hui Hung; Gary Thomas
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

Review 5.  The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release.

Authors:  Stephan Bour; Klaus Strebel
Journal:  Microbes Infect       Date:  2003-09       Impact factor: 2.700

6.  Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery.

Authors:  Matthias Geyer; Haifeng Yu; Robert Mandic; Thomas Linnemann; Yong-Hui Zheng; Oliver T Fackler; B Matija Peterlin
Journal:  J Biol Chem       Date:  2002-05-24       Impact factor: 5.157

7.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

8.  HIV Nef inhibits T cell migration.

Authors:  Evangeline Y Choe; Elena S Schoenberger; Jerome E Groopman; In-Woo Park
Journal:  J Biol Chem       Date:  2002-09-26       Impact factor: 5.157

9.  An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection.

Authors:  Simon Swingler; Beda Brichacek; Jean-Marc Jacque; Catherine Ulich; Jin Zhou; Mario Stevenson
Journal:  Nature       Date:  2003-07-10       Impact factor: 69.504

View more
  15 in total

Review 1.  Cellular restriction factors affecting the early stages of HIV replication.

Authors:  Omar Perez; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

2.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

Review 3.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

4.  Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs.

Authors:  Jenny L Anderson; Adam T Johnson; Jane L Howard; Damian F J Purcell
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

Review 6.  The emerging role of long non-coding RNAs in HIV infection.

Authors:  Daniel C Lazar; Kevin V Morris; Sheena M Saayman
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

7.  Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses.

Authors:  Jan Münch; Devi Rajan; Michael Schindler; Anke Specht; Elke Rücker; Francis J Novembre; Eric Nerrienet; Michaela C Müller-Trutwin; Martine Peeters; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Anke Specht; Carolin Ritter; Kati Pulkkinen; Kalle Saksela; Frank Kirchhoff
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Analysis of dinucleotide signatures in HIV-1 subtype B genomes.

Authors:  Aridaman Pandit; Jyothirmayi Vadlamudi; Somdatta Sinha
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

Review 10.  Tetherin and its viral antagonists.

Authors:  Björn D Kuhl; Vicky Cheng; Mark A Wainberg; Chen Liang
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.